American Renal Associates Holdings Inc (NYSE:ARA) – SunTrust Banks cut their FY2017 EPS estimates for shares of American Renal Associates in a research report issued on Wednesday. SunTrust Banks analyst D. Macdonald now forecasts that the company will post earnings per share of $0.56 for the year, down from their previous estimate of $0.57. SunTrust Banks currently has a “Buy” rating and a $18.00 target price on the stock. SunTrust Banks also issued estimates for American Renal Associates’ Q4 2017 earnings at $0.15 EPS and Q1 2018 earnings at $0.10 EPS.
Several other equities research analysts have also recently commented on the company. Zacks Investment Research raised American Renal Associates from a “hold” rating to a “buy” rating and set a $13.00 target price for the company in a research note on Thursday, November 16th. Leerink Swann reissued an “outperform” rating and issued a $17.00 target price (down from $22.00) on shares of American Renal Associates in a research note on Tuesday, November 21st. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. American Renal Associates presently has an average rating of “Buy” and a consensus price target of $17.75.
American Renal Associates (NYSE:ARA) last released its earnings results on Tuesday, November 14th. The company reported $0.19 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.16 by $0.03. The company had revenue of $187.71 million during the quarter, compared to analysts’ expectations of $194.60 million. American Renal Associates had a positive return on equity of 15.80% and a negative net margin of 2.15%. The business’s revenue for the quarter was down 2.7% on a year-over-year basis. During the same period last year, the firm earned $0.28 EPS.
Several large investors have recently bought and sold shares of ARA. Van Berkom & Associates Inc. lifted its holdings in American Renal Associates by 490.5% during the third quarter. Van Berkom & Associates Inc. now owns 2,191,863 shares of the company’s stock worth $32,812,000 after acquiring an additional 1,820,649 shares in the last quarter. Vanguard Group Inc. lifted its holdings in American Renal Associates by 11.6% during the first quarter. Vanguard Group Inc. now owns 928,768 shares of the company’s stock worth $15,678,000 after acquiring an additional 96,196 shares in the last quarter. TimesSquare Capital Management LLC lifted its holdings in American Renal Associates by 6.7% during the second quarter. TimesSquare Capital Management LLC now owns 1,290,200 shares of the company’s stock worth $23,933,000 after acquiring an additional 80,650 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in American Renal Associates by 2,089.4% during the second quarter. JPMorgan Chase & Co. now owns 72,250 shares of the company’s stock worth $1,340,000 after acquiring an additional 68,950 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in American Renal Associates by 303.9% during the third quarter. Dimensional Fund Advisors LP now owns 50,027 shares of the company’s stock worth $749,000 after acquiring an additional 37,641 shares in the last quarter. Institutional investors and hedge funds own 93.27% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.com-unik.info/2017/12/22/analysts-issue-forecasts-for-american-renal-associates-holdings-incs-fy2017-earnings-ara.html.
American Renal Associates Company Profile
American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.
What are top analysts saying about American Renal Associates? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for American Renal Associates and related companies.